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Abstract
Physician responses to genomic information are vital to the success of precision medicine 
initiatives. We prospectively studied a pharmacogenomics implementation program for the 
propensity of clinicians to select antiplatelet therapy based on CYP2C19 loss-of-function (LOF) 
variants in stented patients. Among 2,676 patients, 514 (19.2%) were found to have a CYP2C19 
variant affecting clopidogrel metabolism. For the majority (93.6%) of the cohort, cardiologists 
received active and direct notification of CYP2C19 status. Over 12 months, 57.6% of poor 
metabolizers and 33.2% of intermediate metabolizers received alternatives to clopidogrel. 
CYP2C19 variant status was the most influential factor impacting the prescribing decision [HR in 
poor metabolizers 8.1, 95% CI (5.4,12.2) and HR 5.0, 95% CI (4.0,6.3) in intermediate 
metabolizers], followed by patient age and type of stent implanted. We conclude that cardiologists 
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tailored antiplatelet therapy for a minority of patients with a CYP2C19 variant and considered 
both genomic and non-genomic risks in their clinical decision-making.
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Introduction
Despite a steep increase in the use of prescription drugs, the striking variability in drug 
response and therapeutic outcomes remain largely unaddressed
1,2. Differences in drug safety 
and efficacy for a growing list of medications are explained, in part, by genomic variation
3
. 
Yet the translation of new pharmacogenomic knowledge into clinical care has been slow
4
, 
prompting calls to bridge the implementation gap by sharing dissemination methods and 
developing best practice guidelines
5–8. A consensus strategy to implement genomic 
medicine is emerging: integrate genomic results into electronic health records (EHRs), 
provide comprehensive genomic clinical decision support (CDS), and educate clinicians to 
effectively use the new biomarkers. To date, there are only a few reports of whether this 
strategy is successful, and little information about how genomic data is integrated with other 
known clinical determinants of drug selection or dosing
9–12.
The case of the antiplatelet drug clopidogrel and variation in CYP2C19 illustrates the 
broader challenge of genome-informed care that also accounts for the full spectrum of drug 
risks and patient context. Clopidogrel is the most commonly used drug for prophylaxis 
against thrombotic complications of percutaneous coronary interventions (PCI). 
Bioactivation is largely dependent on the activity of a hepatic P450 cytochrome enzyme, 
CYP2C19, which has common loss-of- function polymorphisms associated with decreased 
inhibition of ADP-induced platelet aggregation and reduced efficacy
13
. Large observational 
studies have consistently shown that post-PCI patients with a CYP2C19 variant who are 
treated with clopidogrel are at increased risk of stent thrombosis and major adverse events, 
including myocardial infarction, revascularization, stroke, or cardiovascular death 
particularly in the first 30 days following the procedure.
14–17 Prescribing guidelines to 
mitigate the genomic risk have been issued and the Food and Drug Administration (FDA) 
has re-labeled the drug monograph with a Black Box warning for CYP2C19 poor 
metabolizers
18
. Alternatives to standard-dose clopidogrel, the antiplatelet agents prasugrel 
and ticagrelor, both feature superior efficacy and a metabolic pathway that is independent of 
CYP2C19 status. However, both alternate agent carry distinct contraindications, increased 
risks of bleeding in some populations, and higher out-of-pocket costs which must be 
considered by prescribers along with the genomic risks
19–23.
To investigate how physicians have responded to an enterprise-wide pharmacogenomics 
implementation, we prospectively studied antiplatelet prescriptions and interactions with 
clinical decision support for a three-year period involving a large population of patients who 
underwent coronary stenting.
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Between October 1, 2010 and March 30, 2013, 12,157 patients were genotyped through 
PREDICT, a pharmacogenomics program established at Vanderbilt University Medical 
Center
9,10. Of this group, 2,676 received a coronary stent, and 514 (19.2%) were found to 
have at least one loss-of-function allele; 64 (2.4%) were designated as poor metabolizers and 
450 (16.8%) as intermediate metabolizers (Figure 1 and Supplemental Table 1). 
Characteristics of patients as assessed by nursing staff during a pre-catheterization 
evaluation are shown in Table 1 and stratified by drug metabolism phenotype. 
Administratively recorded demographics, cardiac risk factors, rates of prior 
revascularization, indication and urgency of catheterization were similar (pairwise p>0.05) 
in patients with different drug metabolism phenotypes, with the exceptions of hypertension 
and peripheral vascular disease. A substantial proportion (43.0%) of patients in the 
intermediate and poor metabolism groups were already receiving clopidogrel at baseline, but 
very few (4.1%) were already receiving an alternative antiplatelet therapy at the time of 
percutaneous coronary intervention (PCI).
Program interventions
Pharmacist-led surveillance using a computerized dashboard intercepted 481 of 514 (93.6%) 
patients who were candidates for alternate antiplatelet therapy based on poor or intermediate 
drug metabolizer status,recent placement of a coronary stent, and discharge on clopidogrel 
therapy. Surveillance team members notified the attending interventional cardiologist 
directly of the variant status. In the text of the communication, and after review of the 
medical record, surveillance staff recommended a change in therapy for 304 of 481 (79.8%) 
patients. Patients with a documented contraindication (body weight < 60kg, age>75, history 
of stroke or transient ischemic attack for prasugrel; active or recent bleeding event for both), 
did not receive a surveillance recommendation to change therapy. Overall, 130 changes in 
therapy from standard dose clopidogrel by 12 months followed a surveillance intervention.
Among poor or intermediate metabolizer patients for whom clopidogrel therapy was ordered 
during the initial or subsequent hospital stays, 133 (25.9%) of 514 received at least one 
inpatient CDS alert, consisting of an interruptive advisor recommending a switch to an 
alternate antiplatelet therapy. Clinicians accepted the CDS recommendation to switch from 
standard dose clopidogrel to an alternate antiplatelet regimen in 26 of 133 (19.5%) of 
patients. Resident physicians and nurse practitioners, who are the primary users of 
computerized physician order entry (CPOE) in the hospital, encountered all CDS events. 
Inpatient CDS was only triggered in the records of patients who were hospitalized after their 
genomic results were returned. Often, the patient was discharged prior to the return of 
results; however, many patients were re-hospitalized within 12 months, and the CDS was 
triggered when clopidogrel was re-ordered.
Prescription of Alternate Antiplatelet Therapy
Within 12 months post-PCI, 57.6% of poor metabolizers, 33.2% of intermediate 
metabolizers, and 8.3% of non-actionable patients were prescribed an alternative to standard 
dose clopidogrel (Kaplan-Meier estimates; Figure 2); of all patients with a variant, 21% 
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(n-74) were prescribed alternate antiplatelet therapy in the 30 days period following stenting. 
Among patients given alternative agents (n=175), prescribers commonly selected prasugrel 
(89.1%) or ticagrelor (8.6%), but rarely prescribed higher dose clopidogrel (2.3%) reflecting 
the discontinuation of double-dose clopidogrel as a program recommendation early in the 
study. The median time to receive genotype-tailored therapy from the stent date was 22 days 
(IQR 9–44 days) which incorporated genotyping turnaround time (median 6 days [IQR 3–
11]), time to deliver a CDS or surveillance intervention, and time to coordinate care with 
clinicians internal or external to VUMC.
Factors associated with prescription of genotype-tailored therapy
To investigate whether CYP2C19 variants were independently associated with prescription 
of an alternative antiplatelet agent, we constructed a Cox proportional hazards model 
incorporating genotype as well as other important patient factors and clinical context that 
may affect choice of antiplatelet therapy. Patients with poor and intermediate metabolizer 
status were much more likely to be prescribed alternative therapy with a hazard ratio (HR) of 
8.1 [95% CI 5.4, 12.2] and 5.0 [95% CI 4.0,6.3] respectively. Other factors significantly 
associated with changing therapy included drug eluting stent (vs. bare metal stent) with HR 
2.3 (95% CI 1.7, 3.1) and age with HR 0.6 (95% CI 0.5, 0.7) for age > 75 after adjusting for 
weight, gender, race, number of baseline cardiovascular risks, urgency of procedure, prior 
revascularization, concurrent anticoagulation, and physician cluster. Individual physicians 
showed a large and significant variability in responding to clinical guidance based on 
genotype. Among thirteen high-volume cardiologists taking care of at least 40 patients 
within the cohort, the adoption of alternative antiplatelet therapy ranged widely from 23% to 
68% in their patients with a CYP2C19 loss of function variant (Figure 3).
Prescription of genotype-tailored therapy among higher risk subgroups
Of the 514 poor and intermediate metabolizers, 163 patients (31.7%) had at least one 
documented bleeding risk cited by the prasugrel drug label (age ≥ 75, weight ≤ 60 kg, 
history of cerebrovascular disease, or concurrent anticoagulation). There was a significantly 
increased rate of genotype-tailored therapy among patients without one of these bleeding 
risks (Figure 4A: 43.0% vs 21.2%, p<0.001). Additionally, when a genotype result was 
available at the time of first prescribing, genotype-tailored prescribing was increased 
compared to prescribing instances in which the genetic information was available only after 
the initial prescription (Figure 4B: 45.0% vs. 34.2%, p=0.004). Similarly, the timeliness of 
the prescription change was improved by preemptive testing (median 8 days [IQR 1–45 
days] vs 26 days [IQR 13–43 days], p=0.002).
Discussion
In a large implementation of panel-based pharmacogenomic testing, reporting CYP2C19 
variant status to cardiologists caring for patients following a stent resulted in genotype-
tailored antiplatelet therapy in the majority of patients with the highest risk genotype and a 
substantial minority of patients at intermediate genomic risk. While CYP2C19 status was 
most predictive of tailored antiplatelet therapy, patient age and stent type were also 
associated on multivariate analysis, indicating that physicians weighed both genetic and 
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clinical risks prior to prescribing. Additionally, when patients were genotyped preemptively, 
the rate of genotype-tailored therapy increased, reflecting the benefits of having genetic 
information and interpretations available at therapy initiation. Changes to therapy clustered 
during the 30 days post-stent when thrombosis risk is highest but continued to accrue over 
the course of a 12-month period following stent placement.
Several other reports on physician response to pharmacogenomic data provide context and 
comparisons to these results. Desai and colleagues prescreened patients who were clinically 
eligible for intensified antiplatelet therapy and reported that 3/15 (20%) of poor metabolizers 
and 27/92 (29%) intermediate metabolizers were prescribed intensified antiplatelet therapy 
after genetic results, but no explicit clinical guidance, were provided to clinicians and 
patients
24
. The Personalized Medicine Program at the University of Florida reported 56 of 
80 post-PCI patients with CYP2C19 variants received tailored therapy with alternatives to 
clopidogrel
25
. In patients with high-risk coronary disease, Lee and colleagues reported 30% 
of 264 patients received alternative antiplatelet therapy and in contrast to our report, only 
CYP2C19 genotype was predictive of therapy change
26
. Other pharmacogenomic programs 
have reported that clinicians are highly responsive to other drug gene-interactions
11
. 
However, this manuscript is the first study with sufficient prescribing events to examine how 
patient, physician, and program factors influence the implementation success of a precision 
medicine program. As the use of pharmacogenomics in routine clinical care is still new, 
comprehensive studies provide insight into how clinicians approach new personalized 
recommendations.
The study indicated a minority of patients with heterozygous CYP2C19 variant received 
tailored therapy, and analysis of prescribing patterns pointed toward several patient factors 
that influenced antiplatelet decision making in addition to the degree of genetic risk. In 
multivariate analysis, advanced patient age and bare metal stent use were associated with a 
lower rate of tailored therapy in patients with a CYP2C19 variant. Clinicians were likely 
cautioned by the increased number of serious bleeding events in the prasugrel arm of 
TRITON- TIMI 38
21
 among patients 75 and older, which was also reinforced by the 
program’s communication of relative contraindications to prasugrel when present. Other 
physician specific factors have been elicited using survey and interview data published 
separately but obtained from the same population of clinicians
27,28. In these studies, some 
cardiologists expressed uncertainty around the clinical significance of the intermediate 
metabolizer status and the lack of randomized controlled trial data to support use of 
CYP2C19 to tailor antiplatelet therapy. Additionally, physicians cited the cost of ticagrelor 
and prasugrel as a barrier to switching patients who could not afford the higher co-pay.
Several improvements to the implementation design may be needed to reduce the latency 
between testing and decision-making. Turnaround times of first generation 
pharmacogenomics panel tests can be long (median 6 days in our study), and should be 
replaced by newer assays featuring faster sample processing. Turnaround of less than 24 
hours could enable selection of antiplatelet therapy prior to patient discharge, and reduce the 
need for the post-discharge surveillance for abnormal results. Secondly, a greater proportion 
of the cardiovascular population could be genotyped pre-emptively, prompted either by the 
need for an elective cardiovascular procedure, or by the presence of known coronary disease 
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where the need for future antiplatelet therapy is indicated. Finally, the communication of 
variant results and application to the prescription, while still challenging when involving 
clinicians outside of our health system, could be improved through a number of pathways 
including greater ancillary support and development of consensus among specialty 
physicians on how to manage the genetic data.
Our study has several limitations. The study design did not capture the rationale for each 
antiplatelet decision and verify that the clinical decision support recommendations were 
understood or CYP2C19 variant status was appreciated. However, a previous survey of the 
same population of clinicians involved in the program demonstrated a high degree of 
awareness and agreement with the influence of genetic variants on drug prescribing
27
. 
Clinician barriers to following program advice have been previously reported using both 
survey and qualitative methodologies. Clinicians expressed difficulties with understanding 
the established pharmacogenomics nomenclature, concerns for patient non-compliance 
related to the higher out-of-pocket costs for prasugrel or ticagrelor compared to clopidogrel, 
and confusion surrounding the clinical responsibility for the diverse components of a 
pharmacogenomics panel test
27,28.
As a quality improvement program, prescription alterations were determined from electronic 
records and, when absent due to loss of follow-up, the patient was censored at the time of 
the last record. Rates of genotype-tailored therapy may be underestimated, as prescription 
changes that occurred outside of the VUMC electronic prescribing system were not 
recorded. Second, changes to antiplatelet therapy over a one-year period post-coronary stent 
are influenced by considerations other than drug metabolism status, such as out of pocket 
costs, new risks for bleeding, and intervening cardiac events. However, the rate of alternative 
antiplatelet therapy in the non-actionable patients was consistently low throughout this 
period, indicating the genetic risks recorded in the EHR remained influential even after the 
initial episode of care. Finally, the response of clinicians to genomic data will likely vary 
across settings, and the results within an academic medical center may not generalize to 
community physicians without an overarching program to deliver genomic results and 
interpretations.
In conclusion, implementation of PREDICT and routine pharmacogenomics testing of 
cardiac patients strongly influenced provider selection of antiplatelet therapy following 
placement of a coronary stent. With the increasing availability of cost-efficient panel-based 
genotyping technology, genome-guided therapies can be feasibly and effectively integrated 
within routine clinical care.
Methods
Pharmacogenomics implementation
VUMC launched PREDICT in September 2010 as a system that enabled genome-informed 
therapy by storing, interpreting, and disseminating genetic results and therapeutic 
recommendations. As previously described, genetic results were managed over time, 
promoting actionable gene results to the EHR, assigning a drug metabolism phenotype for 
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genotype patterns identified by the panel test, and incorporating the drug metabolism 
phenotype into clinical decision support
9,10,29.
Patients were genotyped for CYP2C19 status as part of PREDICT using a commercial 
pharmacogenomics array (Illumina BeadExpress ADME). Genotyping occurred via one of 
two mechanisms: a) preemptively as part of a strategy to identify patients at high risk for 
receiving future prescriptions for clopidogrel or two other medications with 
pharmacogenomic indications (simvastatin and warfarin)
30
 or b) in preparation for PCI, 
which often entailed coronary stent placement and dual antiplatelet therapy with aspirin and 
a P2Y12 receptor antiplatelet drug. Detected variants were mapped to the descriptive terms 
poor (homozygote/compound heterozygote for loss-of-function alleles), intermediate (one 
loss-of-function allele), normal, rapid, or indeterminate metabolizer status, using internally 
developed translation tables
9
, nearly identical to the approach described by the Clinical 
Pharmacogenomics Implementation Consortium (CPIC)
31
. Program clinical decision 
support (CDS) was triggered only for poor and intermediate metabolizers and advised 
substitution with prasugrel or ticagrelor for standard dose clopidogrel. Both raw (e.g. 
CYP2C19*2/*2) and descriptive (e.g. “poor metabolizer”) results appeared in the laboratory 
and patient summary sections of a patient’s EHR. Clinician education regarding PREDICT 
implementation was conducted through group seminars, mass e-mail communications, and 
via an institutional web site designed for internal and external physician use
32
. Inpatient 
CDS delivered genomic results to prescribing clinicians, including an interruptive advisor 
designed to guide prescribing within the inpatient computerized provider order entry. CDS 
fired when any prescribing clinician attempted to prescribe clopidogrel in the setting of a 
Equivalent outpatient CDS functionality was introduced later in the program course and was 
active during the final 3 months of the analysis period. CYP2C19 results were also delivered 
via a surveillance system designed to intervene on patients with variant results indicating a 
change of antiplatelet therapy was needed and expected to fill the gap when patients had 
infrequent or absent clinical follow-up after genotyping
33
. In the surveillance system, a team 
composed of pharmacists and nurses reviewed a computerized dashboard displaying records 
of CYP2C19 variant patients who were recently discharged on clopidogrel following a 
coronary stent. Surveillance team members directly messaged the attending physician using 
an electronic messaging system built into the EMR. Surveillance was conducted Monday-
Friday excluding holidays. Physicians prescribing antiplatelet therapy for patients who were 
intermediate and poor metabolizers could encounter any combination of these mechanisms; 
only the CDS and surveillance systems offered a direct recommendation to change therapy. 
Throughout the study period, Vanderbilt University Medical Center paid for all genotyping, 
which was conducted within the College of American Pathologists (CAP) accredited and 
Clinical Laboratory Improvement Amendments (CLIA) certified VUMC Molecular 
Diagnostics Laboratory.
Study Population
We selected VUMC patients who received a bare metal stent or drug eluting stent during the 
first 2.5 years of the program (October 1, 2010 and March 31st, 2013) and for whom 
genotype results were recorded within 30 days of the stent date. Patients were divided into 
those who were preemptively genotyped (i.e. the result was available at the time of first 
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antiplatelet prescription) and those who were genotyped following the procedure. We also 
specifically tracked outcomes among patients with a bleeding risk, defined as specific risks 
for prasugrel at the time of stent placement (age ≥ 75 years old, weight < 60 kg, history of 
cerebrovascular disease, or with concomitant use of anticoagulation.)
21,23
Outcome metrics—The primary outcome was the time to a genotype-tailored antiplatelet 
prescription up to 12 months from the stent procedure date. Patient records were reviewed 
for one year or until no further clinical notes were recorded in the EHR. An antiplatelet 
prescription was designated as genotype-tailored if it matched one of the PREDICT program 
recommendations for CYP2C19 variant patients at the time of the prescription. Program 
recommendations were developed internally in 2010, adapted over time to follow CPIC 
guidelines
31
 and described by publications of the Translational Pharmacogenomics Program 
(TPP) of the Pharmacogenomics Research Network
7
. Briefly, physicians caring for patients 
designated as intermediate or poor metabolizers were encouraged to switch their patients’ 
therapy to prasugrel or ticagrelor, unless medical contraindications were present. An option 
to intensify clopidogrel therapy by doubling the loading and maintenance doses was 
included early in the program, but this option was eliminated when evidence from clinical 
trials indicated that a dose of 150mg daily was not sufficient to overcome clopidogrel 
resistance
34–36. As this was an implementation study, patient characteristics and prescription 
outcomes were assessed by automated abstraction of catheterization records for baseline 
information and of prescription records for determination of the primary outcome
37
. The 
Institutional Review Board approved all studies.
Statistical Analysis
Categorical data are reported as frequencies and continuous data are reported as means and 
standard deviations (SD). Kaplan-Meier based time-to-event analysis compared the 
genotype-tailored antiplatelet prescription rate for patients in three CYP2C19 phenotype 
categories (poor, intermediate, and non-actionable metabolizers), and a log-rank test was 
used to test for differences. The non-actionable subgroup included patients with a genotype 
that indicated normal, rapid, and indeterminate metabolizer status, as none of these 
categories triggered a recommendation to change therapy. Patients were censored from the 
analysis when their EHRs reflected no further clinical notes and no updates to their 
medication lists. The clinician response to genotyping was also examined in a Cox 
Proportional Hazards model incorporating poor and intermediate metabolizer status 
separately as well as demographics (age, gender race), stent type (drug-eluting stent vs bare 
metal stent. The impact of bleeding risks (age ≥ 75, weight < 60 kg, history of 
cerebrovascular disease, or concomitant anticoagulation) at time of stent placement was also 
analyzed in pre-determined subgroups. The Institutional Review Board approved all studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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What is the current knowledge of the topic?
Clopidogrel is recommended as part of dual antiplatelet therapy to prevent thrombotic 
complications after coronary stent placement. The prodrug is metabolized into its active 
form by the CYP enzyme system, and variants in CYP2C19 are associated with adverse 
cardiovascular outcomes following the stent procedure. Guidelines issued by the Clinical 
Pharmacogenomics Implementation Consortium recommend a change in therapy in this 
scenario, while the latest American College of Cardiology/American Heart Association 
guidelines classify CYP2C19 testing as a IIb recommendation (testing may be 
considered.)
What question did this study address?
We examined whether an implementation study reporting CYP2C19 variant status to the 
Electronic Medical Record successfully influenced clinicians’ prescribing of antiplatelet 
therapy after stent placement.
What does this study add to our knowledge?
Translating genotype guided therapy to clinical practice can be successfully scaled across 
an enterprise with sufficient support of clinical pharmacists and clinical decision support. 
Clinician response is sensitive to both the level of genomic risk as well as non-genomic 
prescribing factors.
How might this change clinical pharmacology and therapeutics?
The findings support the creation of programs in precision medicine which target 
CYP2C19 variants to tailor antiplatelet therapy following percutaneous coronary 
interventions. It also aids the interpretation of future observational studies that examine 
how adoption of CYP2C19 testing impacts clinical outcomes.
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Flow of patients through implementation program
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Cumulative incidence of alternative antiplatelet therapy by CYP2C19 drug metabolism 
category (N=2676)
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Response of individual higher-volume cardiologists with greater than 40 subjects in cohort 
in patient populations with and without a CYP2C19 loss-of-function variant
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Cumulative incidence of genotype tailored therapy among patients with intermediate or poor 
metabolizer phenotype for clopidogrel by (A) bleeding risk and (B) timing of genotype 
(N=514)
Bleeding risks include age ≥ 75, weight < 60 kg, history of cerebrovascular disease, or 
concomitant anticoagulation (warfarin, dabigatran, enoxaparin, fondaparinux, or 
rivaroxaban) at time of stent placement.
Preemptive genotyping indicated result available prior to coronary stent placement. Post-
procedure genotyping indicated result available within 30 days of coronary stent placement.
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